Delta Sleep-Inducing Peptide (DSIP)
Also known as: DSIP, delta sleep-inducing peptide, delta-sleep-inducing peptide, WAGGDASGE, Deltaran
Neuropeptide / Regulatory peptide (nonapeptide)
What it is
DSIP is a neuropeptide people use for sleep improvement, pain reduction, and stress recovery. It was originally identified as a sleep-promoting signal, though its relationship to sleep is not firmly established. Not FDA-approved; evidence from small and older human studies; commonly available as a research compound.
The scientific side
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide with multifunctional regulatory activity. It was originally isolated from rabbit cerebral venous blood in 1977 and initially characterized as a sleep-promoting factor, though its link to sleep has not been definitively established. Its biosynthetic origin remains obscure; no DSIP gene or protein precursor has been confirmed, though JmjC-domain-containing histone demethylases (JMJD1B gene) have been proposed as possible precursors based on sequence homology (PMID 21262293; PMID 24397026). DSIP has been shown to influence oxidative phosphorylation in rat brain mitochondria, significantly increasing the rate of phosphorylated respiration (V3) and the respiratory control ratio. It modulates neurotransmitter systems including Met-enkephalin release, spinal noradrenergic pathways mediating antinociception, and GABAergic Cl⁻ flux. DSIP also affects thermoregulation via 5-HT1A and dopaminergic mechanisms (PMID 8015981; PMID 2322843). Stress-protective and adaptive activity has been described across multiple stressor types. DSIP displays a saturable, high-affinity transport mechanism at the blood-brain barrier, and also enters CSF to a slight or moderate extent in intact form. It is rapidly degraded in blood, primarily by cleavage of the N-terminal tryptophan via aminopeptidases (PMID 3628078; PMID 8474631). Plasma DSIP-like immunoreactivity decreases at the initiation of sleep. A phosphorylated analogue (P-DSIP, phosphorylated at Ser7) shows slower degradation and different pharmacodynamic properties (PMID 3628078; PMID 2496423). Recovery-enhancing and circadian/mitochondrial regulatory roles are noted in orthopaedic-relevant reviews.
Class: Neuropeptide / Regulatory peptide (nonapeptide)
Administration & storage
- Administration
- Slow intravenous infusion (PMID: 6895513)Intravenous injection (PMID: 7028502; PMID: 3792404; PMID: 6548969; PMID: 6548967)Subcutaneous injection — animal studies (PMID: 6548967)Intraperitoneal injection — animal studies (PMID: 22432135; PMID: 12668217; PMID: 15911358)Intranasal administration — animal studies (PMID: 34500605)Intracerebroventricular injection/infusion — animal studies (PMID: 2496423; PMID: 11525128; PMID: 2713670)
- Storage
- Storage conditions for DSIP are not described in the reviewed abstracts. No storage or stability guidance appears in the provided literature.
- Cautions
- In human clinical studies, DSIP was generally reported as well-tolerated; headaches were reported by a few patients in the withdrawal treatment study; no psychologic, physiologic, or biochemical side effects were observed in early volunteer studies.,DSIP is rapidly degraded in blood by aminopeptidase cleavage of the N-terminal tryptophan, contributing to variable in vivo effects; this instability may result in inconsistent pharmacological outcomes (PMID: 3628078; PMID: 8474631).,Slow intravenous injection was described as essential in human studies; rapid injection may alter tolerability or efficacy.,A bell-shaped dose-response curve has been reported in multiple animal experiments, meaning doses above or below the effective range may be inactive or produce different effects (PMID: 6145137; PMID: 2322843; PMID: 6548967).,No formal human pharmacokinetic, long-term safety, or randomized controlled trial data were identified in the reviewed abstracts; use outside of controlled research settings is not supported by the available evidence. Sterile technique is essential for any injectable preparation.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Sleep promotion / insomnia treatment Human observational
- Acute intravenous DSIP (25 nmol/kg) in 6 middle-aged chronic insomniacs produced longer sleep duration, higher sleep quality, fewer interruptions, slightly more REM sleep, with no daytime sedation or other side effects. PMID 7028502 Schneider-Helmert & Schoenenberger (1981) Experientia
- In 6 healthy volunteers (double-blind cross-over), DSIP (25 nmol/kg IV, morning) increased total sleep time by 59% within 130 min. Delayed effects included shorter sleep onset and better sleep efficiency. Well-tolerated, no psychologic, physiologic, or biochemical side effects. PMID 6895513 Schneider-Helmert et al. (1981) Int J Clin Pharmacol Ther Toxicol
- Five human studies with single and repeated IV DSIP injections; complete normalization of disturbed sleep achieved after four consecutive injections to insomniacs. Slow injection was essential. Compatibility was good. PMID 6689058 Schneider-Helmert & Schoenenberger (1983) Neuropsychobiology
- Double-blind studies in insomniacs showed improvement of sleep following single dose treatments and repeated injections. A case study described DSIP efficacy on narcolepsy. PMID 3758119 Schneider-Helmert (1984) Eur Neurol
- Single injections of 25 nmol/kg improved sleep in insomniacs; repeated administration showed buildup with normalization of sleep structure after four administrations. PMID 6391925 Schneider-Helmert (1984) Eur Neurol
- 18 chronic insomniacs received 6 × 30 nmol/kg IV over one week. Middle-aged insomniacs normalized sleep by end of administration; elderly insomniacs reached normalization during follow-up. Effects correlated with degree of sleep disturbance. PMID 3792404 Schneider-Helmert (1986) Eur Neurol
- Open study: 7 patients with severe insomnia received 10 injections of DSIP. In all but 1, sleep normalized for 3–7 months follow-up. PMID 6391926 Kaeser (1984) Eur Neurol
- Case report: DSIP treatment advanced main sleep phase by 5 hours in a patient with chronic delayed sleep phase insomnia and flunitrazepam dependence, with complete benzodiazepine withdrawal. PMID 3582201 Schneider-Helmert et al. (1987) Dtsch Med Wochenschr
- Narcolepsy treatment Human observational
- Repeated DSIP injections in a 35-year-old male narcoleptic reduced frequency of sleep attacks and increased activity, alertness, and performance during daytime. Sleep period was compressed with enhanced REM sleep. PMID 6548968 Schneider-Helmert (1984) Eur Neurol
- Alcohol and opiate withdrawal Human observational
- DSIP administered IV to 107 inpatients with alcohol (n=47) or opiate (n=60) withdrawal. Clinical symptoms and signs disappeared or improved markedly in ~97% of opiate and ~87% of alcohol addicts. Tolerance was good; headaches reported by a few patients. Anxiety was slower to decrease. PMID 6548969 Dick et al. (1984) Eur Neurol
- Chronic pain treatment Human observational
- Pilot study in 7 patients with migraine, vasomotor headaches, chronic tinnitus, and psychogenic pain. DSIP IV on 5 consecutive days followed by 5 injections every 48–72 h significantly lowered pain levels in 6 of 7 patients. Simultaneous significant reduction of comorbid depressive states was observed. PMID 6548970 Larbig et al. (1984) Eur Neurol
- Antiepileptic / anticonvulsant activity Animal studies only
- DSIP and analogue DSIP-12 (i.p.) significantly increased delta and theta frequency bands and decreased incidence, mean seizure grade, and duration of metaphit-induced convulsions in rats. DSIP-12 was more efficient than DSIP. PMID 15911358 Stanojlović et al. (2005) Seizure
- In 720 male rats, DSIP produced higher pentylenetetrazol seizure thresholds during night periods and offered improved protection during night hours compared to saline control. PMID 8483798 Yehuda & Mostofsky (1993) Peptides
- DSIP and related peptide KND showed anticonvulsive effects in vivo in rats. PMID 24397026 Mikhaleva et al. (2013) Bioorg Khim
- Stress protection / antistress Mixed
- Intraperitoneal DSIP (30 µg/kg) reduced stress-induced Fos expression in pPVN and limbic regions, particularly in rats predisposed to emotional stress. PMID 22432135 Sudakov et al. (2001) Stress
- DSIP is described as an antistress oligopeptide increasing resistance to stressful impacts in humans, alongside substance P, beta-endorphin, and semax. PMID 19140465 Sudakov (2008) Vestn Ross Akad Med Nauk
- DSIP (25 µg/kg IV) prevented hyposomnia after a stressful situation in rabbits. PMID 6548967 Scherschlicht et al. (1984) Eur Neurol
- Neuroprotection / stroke recovery Animal studies only
- Intranasal DSIP (120 µg/kg, 8 days) in SD rats with focal stroke (MCAO model) led to significantly accelerated recovery of motor functions in the rotarod test, though infarction volume reduction was not significant. PMID 34500605 Tukhovskaya et al. (2021) Molecules
- Mitochondrial respiration enhancement / hypoxia protection Animal studies only
- DSIP significantly increased V3 (phosphorylated respiration rate), enhanced respiratory control ratio, and rate of ADP phosphorylation in rat brain mitochondria in vitro. Pretreatment with DSIP (120 µg/kg i.p.) prior to hypoxia in rats completely inhibited hypoxia-induced reduction of mitochondrial respiratory activity PMID 12668217 Khvatova et al. (2003) Peptides
- Antioxidant / detoxification (DSIP analogues) Animal studies only
- 16 DSIP analogues exhibited considerable direct antioxidative activity in vitro. Analogue ID-6 showed AOA comparable to vitamin C and β-carotene and the most pronounced detoxifying effect against cisplatin in mice, reducing animal death from acute cisplatin toxicity to 17% versus 50–67% in controls. PMID 25898718 Mikhaleva et al. (2014) Bioorg Khim
- Antinociception / pain modulation Animal studies only
- DSIP (1 pM–1 nM) significantly stimulated calcium-dependent release of immunoreactive Met-enkephalin from rat lower brainstem slices, suggesting indirect action on opioid receptors for antinociceptive effects. PMID 2706459 Nakamura et al. (1989) Brain Res
- ICV DSIP antinociceptive effects in mice were significantly reduced by reserpine (monoamine depletion) and antagonized by intrathecal phentolamine or yohimbine (alpha-adrenergic blockers), but not methysergide. Implicates descending noradrenergic systems. PMID 2713670 Nakamura et al. (1989) Brain Res
- Sleep EEG and CSF correlates in psychiatric/neurological disease Human observational
- CSF DSIP-LI in 15 drug-free male schizophrenic subjects was significantly correlated with stage 3 sleep and delta sleep during the first NREM period and negatively with stage 2% sleep on polysomnography. PMID 1475566 van Kammen et al. (1992) Sleep
- CSF DSIP-LI was significantly decreased in patients with mid-to-late stage Alzheimer's dementia, multi-infarct dementia, Parkinson's disease, vascular disease, and communicating hydrocephalus compared to age-matched controls. DSIP-LI positively correlated with age in both control groups. PMID 2448424 Ernst et al. (1987) J Neurol
- Plasma DSIP-LI was significantly elevated in suicidal patients with major depressive disorder (MDD, p<0.005). Significant correlation between predexamethasone cortisol and predexamethasone DSIP-LI in healthy controls suggested glucocorticoid involvement in DSIP regulation. PMID 9606527 Westrin et al. (1998) Biol Psychiatry
- Sleep promotion via fusion peptide (DSIP-CBBBP) — preclinical Animal studies only
- DSIP fused with a blood-brain barrier crossing peptide (DSIP-CBBBP) expressed in Pichia pastoris showed better restorative effect than DSIP alone on neurotransmitter imbalance (5-HT, glutamate, dopamine, melatonin) and enhanced sleep in a PCPA-induced insomnia mouse model. PMID 39444618 Mu et al. (2024) Front Pharmacol
Safety signals
- Headaches reported by a few patients during intravenous DSIP treatment for alcohol and opiate withdrawal (107-patient clinical study). PMID 6548969
- Slight arousing/activating effect (rather than sedating) observed in the first hour after intravenous injection in human insomnia studies; sleep-promoting effects only emerged in the second hour. PMID 7028502
- Rapid degradation in blood (release of tryptophan, rate dependent on temperature and species) may contribute to variable and inconsistent in vivo effects. PMID 3628078
- Bell-shaped dose-response relationships reported in animal studies across multiple experimental settings; doses outside the effective range were ineffective or produced different effects. PMID 6548967
- DSIP analogue [beta-Ala2]DSIP significantly suppressed sleep in rabbits in contrast to the sleep-promoting effects of parent DSIP or other analogues, suggesting that structural modifications can reverse biological activity. PMID 11525128
Contraindications
- No explicit contraindications are stated in the reviewed abstracts. The reviewed literature does not identify specific clinical contraindications for DSIP administration. PMID 16539679
Protocol
100 mcg subcutaneous injection, once daily, 30-60 min before sleep. Cycle: 1-2 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous | 25 nmol/kg body weight | Single acute injection | human | Research PMID 7028502 |
| Slow intravenous infusion | 25 nmol/kg | Single morning infusion | human | Research PMID 6895513 |
| Intravenous injection | 25 nmol/kg body weight | Single injections; repeated administrations described | human | Research PMID 6391925 |
| Intravenous | 6 × 30 nmol/kg body weight | One week (6 injections) | human | Research PMID 3792404 |
| Intravenous | 5 injections on consecutive days, then 5 injections every 48–72 h (dose not specified in abstract) | ~2 weeks | human | Research PMID 6548970 |
| Intravenous | Not fully specified; single and repeated IV injections studied | Single and repeated administrations | human | Research PMID 6689058 |
| Intravenous; subcutaneous | 25 µg/kg IV; 1 mg/kg subcutaneous (rabbits); 25 µg/kg IV, 100 µg/kg subcutaneous (cats); 25.5 µg/kg IV and doses beyond 85 µg/kg subcutaneous (morphine-dependent mice) | Single doses (various experiments) | animal | Research PMID 6548967 |
| Intraperitoneal | 30 µg/kg | Single intraperitoneal injection | animal | Research PMID 22432135 |
| Intraperitoneal | 120 µg/kg | Single pretreatment prior to hypoxia | animal | Research PMID 12668217 |
| Intranasal | 120 µg/kg | 8 days (applied 60 min prior to occlusion and for 7 days after reperfusion) | animal | Research PMID 34500605 |
| Intracerebroventricular infusion | 0.5 nmol P-DSIP (phosphorylated analogue); doses ranging 0.025–25 nmol tested | Continued 10-h nocturnal intracerebroventricular infusion | animal | Research PMID 2496423 |
| Intracerebroventricular (lateral ventricle) | Peptides injected into lateral ventricle of cerebrum (doses not fully specified in abstract) | Single injections, 7–12 h monitoring | animal | Research PMID 45118 |
| Not specified (i.p. context for apomorphine model) | Minimal effective dose 10 ng; maximal effective dose 1 µg (dose-response relationship: inverted bell-shape) | Single injection | animal | Research PMID 2322843 |
| In vitro (superfused brain slices) | 1 pM–1 nM | In vitro | in_vitro | Research PMID 2706459 |
| subcutaneous injection | 100 mcg | once daily, administered 30-60 minutes before sleep · 1-2 weeks | biohackers and sleep-optimization enthusiasts seeking improved sleep quality | [Community] |
| subcutaneous injection | 200 mcg | once daily, administered 30-60 minutes before sleep · 1-2 weeks | biohackers and sleep-optimization enthusiasts who found 100 mcg insufficient | [Community] |
| subcutaneous injection | 500 mcg | once daily, administered before sleep · 1-2 weeks | experienced biohackers and heavier users seeking pronounced sedative/sleep effects | [Community] |
| subcutaneous injection | 200-500 mcg | once daily before sleep, for 5 days on / 2 days off · 4-6 weeks | biohackers running longer-term DSIP cycles for chronic sleep issues or stress management | [Community] |
| subcutaneous injection | 100 mcg | once daily in the morning · 1-2 weeks | biohackers and individuals using DSIP for stress and anxiety reduction rather than direct sleep induction | [Community] |
| intranasal | 200 mcg | once daily, 30-60 minutes before sleep · 1-2 weeks | biohackers who prefer needle-free administration for sleep optimization | [Community] |
| subcutaneous injection | 100-200 mcg | once daily before sleep, stacked with other peptides · 2-4 weeks | biohackers stacking DSIP with peptides such as Epithalon or Selank for combined sleep and recovery/anti-aging effects | [Community] |
| subcutaneous injection | 300 mcg | once daily before sleep · 1-2 weeks | biohackers seeking a mid-range dose between standard 200 mcg and higher 500 mcg options | [Community] |
Blends containing this peptide
All studies (41)
- PMID 1475566 Human observational
Sleep EEG and CSF correlates in psychiatric/neurological disease - PMID 2448424 Human observational
Sleep EEG and CSF correlates in psychiatric/neurological disease - PMID 3582201 Human observational
Sleep promotion / insomnia treatment - PMID 3758119 Human observational
Sleep promotion / insomnia treatment - PMID 3792404 Human observational
Sleep promotion / insomnia treatment - PMID 6391925 Human observational
Sleep promotion / insomnia treatment - PMID 6391926 Human observational
Sleep promotion / insomnia treatment - PMID 6548968 Human observational
Narcolepsy treatment - PMID 6548969 Human observational
Alcohol and opiate withdrawal - PMID 6548970 Human observational
Chronic pain treatment - PMID 6689058 Human observational
Sleep promotion / insomnia treatment - PMID 6895513 Human observational
Sleep promotion / insomnia treatment - PMID 7028502 Human observational
Sleep promotion / insomnia treatment - PMID 9606527 Human observational
Sleep EEG and CSF correlates in psychiatric/neurological disease - PMID 6548967 Mixed
Stress protection / antistress - PMID 19140465 Mixed
Stress protection / antistress - PMID 22432135 Mixed
Stress protection / antistress - PMID 45118
Peptides injected into lateral ventricle of cerebrum (doses not fully specified in abstract) Intracerebroventricular (lateral ventricle) (animal) - PMID 1666953
- PMID 2322843
Minimal effective dose 10 ng; maximal effective dose 1 µg (dose-response relationship: inverted bell-shape) Not specified (i.p. context for apomorphine model) ( - PMID 2496423
0.5 nmol P-DSIP (phosphorylated analogue); doses ranging 0.025–25 nmol tested Intracerebroventricular infusion (animal) - PMID 2547200
- PMID 2706459 Animal studies only
Antinociception / pain modulation - PMID 2713670 Animal studies only
Antinociception / pain modulation - PMID 3628078
Rapid degradation in blood (release of tryptophan, rate dependent on temperature and species) may contribute to variable and inconsistent in vivo effects. - PMID 6145137
- PMID 6304442
- PMID 8015981
- PMID 8474631
- PMID 8483798 Animal studies only
Antiepileptic / anticonvulsant activity - PMID 8745061
- PMID 11525128
DSIP analogue [beta-Ala2]DSIP significantly suppressed sleep in rabbits in contrast to the sleep-promoting effects of parent DSIP or other analogues, suggesting - PMID 12668217 Animal studies only
Mitochondrial respiration enhancement / hypoxia protection - PMID 15911358 Animal studies only
Antiepileptic / anticonvulsant activity - PMID 16539679
No explicit contraindications are stated in the reviewed abstracts. The reviewed literature does not identify specific clinical contraindications for DSIP admin - PMID 21262293
- PMID 24397026 Animal studies only
Antiepileptic / anticonvulsant activity - PMID 25898718 Animal studies only
Antioxidant / detoxification (DSIP analogues) - PMID 34500605 Animal studies only
Neuroprotection / stroke recovery - PMID 39444618 Animal studies only
Sleep promotion via fusion peptide (DSIP-CBBBP) — preclinical - PMID 41490200